about
Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: analysis of data from a prospective clinical trial.Inferring positions of tumor and nodes in Stage III lung cancer from multiple anatomical surrogates using four-dimensional computed tomographyUpper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus.Smoking is associated with worse outcomes in patients with prostate cancer treated by radical radiotherapy.Impact of patient selection, disease progression, and adverse events on esophageal cancer outcomes after trimodality therapy.Radical Treatment of Stage II Non-small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes.Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.Identifying barriers to accrual in radiation oncology randomized trials.Quantitative texture analysis on pre-treatment computed tomography predicts local recurrence in stage I non-small cell lung cancer following stereotactic radiation therapy.Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1-3 metastases.The Canadian Association of Radiation Oncology Scope of Practice Guidelines for Lung, Liver and Spine Stereotactic Body RadiotherapyPretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of p
P50
Q33423404-BAAFF069-448E-4C65-B7AE-D5DFE6AFCCE0Q34005412-F9861C0D-BE65-4301-B714-95591D9037F6Q34845036-64061F50-8784-4D30-B7DF-F820F8F8D353Q36682293-3F530A30-0325-4B28-A530-A4BDF6E68D85Q38043735-07A0EA38-84ED-479E-BA40-AA082956F1D4Q38677569-C8D4F773-96C6-4113-B5B0-07D9F8FBE0E5Q38895662-D9F0D436-B080-45D2-B657-617CF4D3F33FQ41380574-B8B51B2A-0094-414B-B02F-1F76D214D876Q46984047-D8054001-BCE5-4A73-B463-03426663F57CQ47158489-D4598EF8-736A-4C8C-B20D-10A5079BF737Q47191934-A50798AE-254E-4B97-A885-A71D6DED115DQ47772412-C1846951-5DCF-4E21-B5C2-CC68AAC158F3Q61771667-8EBB37DF-FA81-4C74-B283-7A3C06B15EDFQ87072812-9F2DDF0D-4C2E-43AF-9584-1ECC5786F12A
P50
description
onderzoeker
@nl
researcher
@en
researcher
@en-gb
հետազոտող
@hy
name
Jason Pantarotto
@ast
Jason Pantarotto
@en
Jason Pantarotto
@en-gb
Jason Pantarotto
@es
Jason Pantarotto
@nl
Jason Pantarotto
@sl
type
label
Jason Pantarotto
@ast
Jason Pantarotto
@en
Jason Pantarotto
@en-gb
Jason Pantarotto
@es
Jason Pantarotto
@nl
Jason Pantarotto
@sl
prefLabel
Jason Pantarotto
@ast
Jason Pantarotto
@en
Jason Pantarotto
@en-gb
Jason Pantarotto
@es
Jason Pantarotto
@nl
Jason Pantarotto
@sl
P106
P1153
25923575300
P31
P496
0000-0002-8000-9704